Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | HRH2 | P25021 | 10/20 | 0.51 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6827713 | 0.88 | SLC6A4 (0.50) | DRD2HTR6HRH2HTR2AHTR2C | |
| SCHEMBL3115404 | 0.84 | DRD2 (0.51) | DRD2HTR6HRH2 | |
| SCHEMBL6782119 | 0.76 | HRH2 (0.64) | HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL6824723 | 0.76 | HTR6 (0.48) | HTR6HRH2HTR2C | |
| SCHEMBL6780881 | 0.75 | HRH2 (0.71) | HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL6781730 | 0.73 | HRH2 (0.59) | HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL6781803 | 0.73 | HRH2 (0.65) | HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL6780893 | 0.72 | HRH2 (0.70) | HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL6777121 | 0.72 | DRD2 (0.62) | DRD2HTR6HRH2HTR2AHTR2C | |
| SCHEMBL6780310 | 0.71 | HRH2 (0.72) | HRH2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004007493-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| WO-2004007493-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |